Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study

BACKGROUND: Brolucizumab has recently been approved in Europe as a novel treatment for patients with neovascular age-related macular degeneration (nAMD). We report on early experiences with real-world outcomes of switch to brolucizumab therapy in previously anti-vascular endothelial growth factor (a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bulirsch, Louisa Maria, Saßmannshausen, Marlene, Nadal, Jennifer, Liegl, Raffael, Thiele, Sarah, Holz, Frank G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411904/
https://www.ncbi.nlm.nih.gov/pubmed/33846161
http://dx.doi.org/10.1136/bjophthalmol-2020-318672

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411904/
https://www.ncbi.nlm.nih.gov/pubmed/33846161
http://dx.doi.org/10.1136/bjophthalmol-2020-318672

Ejemplares similares